Valuation: Mendus AB

Market Cap 350M 35.98M 31.59M 29.07M 27.09M 51.09M 3.42B 52.13M 135M 1.68B 135M 132M 5.84B P/E 2026 *
-3.73x
P/E 2027 * -6.34x
Enterprise Value 28.39M 2.92M 2.56M 2.36M 2.2M 4.15M 278M 4.23M 11M 136M 10.97M 10.73M 474M EV / Sales 2026 *
3.17x
EV / Sales 2027 * 0.68x
Free-Float
30.82%
Yield 2026 *
-
Yield 2027 * -
1 day-1.55%
1 week-13.77%
Current month-1.55%
1 month+7.55%
3 months+26.81%
6 months+1.79%
Current year+1.79%
1 week 5.55
Extreme 5.55
6.51
1 month 4.9
Extreme 4.9
7.49
Current year 3.86
Extreme 3.86
7.49
1 year 3.86
Extreme 3.86
10.98
3 years 3.86
Extreme 3.86
16.38
5 years 3.86
Extreme 3.86
126.8
10 years 3.86
Extreme 3.86
640
Manager TitleAgeSince
Chief Executive Officer 54 16/03/2021
Chief Executive Officer 76 13/12/2019
Director of Finance/CFO 60 28/02/2021
Director TitleAgeSince
Chairman 52 22/01/2021
Director/Board Member 64 01/01/2020
Director/Board Member 74 01/01/2013
Date Insider Type Main position Quantity % Market Cap.
28/02/22Buy

Chief Technology Officer

10,000 0.0050%
24/02/22Buy

Chief Financial Officer

20,000 0.0100%
24/02/22Buy

Chief Financial Officer

10,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
-1.55%-13.77%-26.74%-45.92% 35.98M
+3.08%+6.47%-0.25%+5.47% 48.62B
+0.12%+10.45%+408.29%+600.97% 39.86B
+5.17%+9.47%+24.96%-9.60% 33.91B
+2.02%+4.91%+18.59%+63.06% 32.32B
+0.69%+1.04%+14.23%+30.86% 24.73B
+0.40%+12.51% - - 16.63B
+2.64%+6.00%+69.30%+126.33% 15.52B
-0.15%+2.15%+12.64%+17.71% 13.63B
+0.77%+10.67%+17.58%-30.04% 13.41B
Average +1.32%+4.97%+59.85%+84.32% 23.87B
Weighted average by Cap. +1.96%+7.14%+88.03%+128.34%

Financials

2026 *2027 *
Net sales 8.95M 921K 808K 744K 693K 1.31M 87.54M 1.33M 3.47M 42.97M 3.46M 3.38M 150M 224M 23.1M 20.28M 18.67M 17.39M 32.8M 2.2B 33.47M 86.98M 1.08B 86.72M 84.84M 3.75B
Net income -163M -16.77M -14.72M -13.55M -12.63M -23.81M -1.59B -24.3M -63.14M -782M -62.95M -61.59M -2.72B -18.59M -1.91M -1.68M -1.55M -1.44M -2.72M -182M -2.77M -7.2M -89.25M -7.18M -7.03M -311M
Net Debt -321M -33.05M -29.02M -26.71M -24.89M -46.95M -3.14B -47.9M -124M -1.54B -124M -121M -5.37B -197M -20.27M -17.79M -16.38M -15.26M -28.78M -1.93B -29.37M -76.33M -946M -76.1M -74.45M -3.29B
Logo Mendus AB
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Employees
19
Date Price Change Volume
01/07/26 SEK 5.700 -1.55% 13,073
30/06/26 SEK 5.790 -0.17% 11,765
29/06/26 SEK 5.800 -6.45% 41,496
26/06/26 SEK 6.200 -4.91% 29,388
25/06/26 SEK 6.520 -1.36% 24,399
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
5.700SEK
Average target price
16.00SEK
Spread / Average Target
+180.70%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMU Stock